Published in
American Society of Hematology, Blood Advances, 20(3), p. 3062-3069, 2019
DOI: 10.1182/bloodadvances.2019000593
Links
Tools
Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy
Journal article published in 2019 by
Mazyar Shadman,
Jordan Gauthier,
Kevin A. Hay 
,
Jenna M. Voutsinas,
Filippo Milano,
Ang Li ,
Alexandre V. Hirayama ,
Mohamed L. Sorror,
Sindhu Cherian,
Xueyan Chen,
Ryan D. Cassaday ,
Brian G. Till,
Ajay K. Gopal ,
Brenda M. Sandmaier ,
David G. Maloney
and other authors.
,
Jenna M. Voutsinas,
Filippo Milano,
Ang Li ,
Alexandre V. Hirayama ,
Mohamed L. Sorror,
Sindhu Cherian,
Xueyan Chen,
Ryan D. Cassaday ,
Brian G. Till,
Ajay K. Gopal ,
Brenda M. Sandmaier ,
David G. Maloney
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Postprint:
archiving forbidden
Data provided by 
Abstract
Key Points The toxicity of allo-HCT in patients with prior CAR-T therapy was not higher than what is expected in these high-risk patients. In ALL patients, there seems to be a benefit from earlier utilization of allo-HCT after CAR-T therapy.